Shares of Summit Therapeutics PLC (SMMT) have gained 2.8% over the past four weeks to close the last trading session at $21.2, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of$34.56 indicates a potential upside of 63%.The mean estimate comprises nine short-term price targets with a standard deviation of $10. While the lowest estimate of$12.00 indicates a 43.4% decline from the ...